Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma

A phase I/II trial

C. Collins, J. F. Eary, G. Donaldson, C. Vernon, N. E. Bush, S. Petersdorf, Robert B Livingston, E. E. Gordon, C. R. Chapman, F. R. Appelbaum

Research output: Contribution to journalArticle

242 Citations (Scopus)

Abstract

Samarium-153-ethylenediaminetetramethylene phosphonic acid (EDTMP), a bone-seeking radiopharmaceutical, was given to prostate cancer patients in a dose escalation protocol for pain palliation to determine the maximally tolerated dose. Fifty-two patients with hormone refractory prostate cancer with bony metastases were treated with doses beginning at 0.5 mCi/kg (18.5 MBq/kg), escalating in 0.5-mCi (18.5 MBq) increments to 3.0 mCi/kg (111 MBq/kg). Pain response after treatment was assessed as well as hematologic and serum chemistry parameters. Pain palliation with a mean duration of 2.6 mo was present in 74% of the patients. Toxicity was exclusively hematologic at the highest dose levels. No infectious or bleeding complications occurred, with 45 of the 52 (86%) patients demonstrating complete hematologic recovery. Patients receiving higher doses had significantly greater reductions in serum prostate specific antigen and serum prostatic acid phosphatase levels. The patients receiving greater doses also showed a trend toward improved survival.

Original languageEnglish (US)
Pages (from-to)1839-1844
Number of pages6
JournalJournal of Nuclear Medicine
Volume34
Issue number11
StatePublished - 1993
Externally publishedYes

Fingerprint

Samarium
Prostate
Hormones
Neoplasm Metastasis
Carcinoma
Bone and Bones
Pain
Prostatic Neoplasms
Serum
Maximum Tolerated Dose
Radiopharmaceuticals
Prostate-Specific Antigen
phosphonic acid
Hemorrhage
Survival

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Collins, C., Eary, J. F., Donaldson, G., Vernon, C., Bush, N. E., Petersdorf, S., ... Appelbaum, F. R. (1993). Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. Journal of Nuclear Medicine, 34(11), 1839-1844.

Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma : A phase I/II trial. / Collins, C.; Eary, J. F.; Donaldson, G.; Vernon, C.; Bush, N. E.; Petersdorf, S.; Livingston, Robert B; Gordon, E. E.; Chapman, C. R.; Appelbaum, F. R.

In: Journal of Nuclear Medicine, Vol. 34, No. 11, 1993, p. 1839-1844.

Research output: Contribution to journalArticle

Collins, C, Eary, JF, Donaldson, G, Vernon, C, Bush, NE, Petersdorf, S, Livingston, RB, Gordon, EE, Chapman, CR & Appelbaum, FR 1993, 'Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial', Journal of Nuclear Medicine, vol. 34, no. 11, pp. 1839-1844.
Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. Journal of Nuclear Medicine. 1993;34(11):1839-1844.
Collins, C. ; Eary, J. F. ; Donaldson, G. ; Vernon, C. ; Bush, N. E. ; Petersdorf, S. ; Livingston, Robert B ; Gordon, E. E. ; Chapman, C. R. ; Appelbaum, F. R. / Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma : A phase I/II trial. In: Journal of Nuclear Medicine. 1993 ; Vol. 34, No. 11. pp. 1839-1844.
@article{5bd5b99ad82b4ffe929f51337673717f,
title = "Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial",
abstract = "Samarium-153-ethylenediaminetetramethylene phosphonic acid (EDTMP), a bone-seeking radiopharmaceutical, was given to prostate cancer patients in a dose escalation protocol for pain palliation to determine the maximally tolerated dose. Fifty-two patients with hormone refractory prostate cancer with bony metastases were treated with doses beginning at 0.5 mCi/kg (18.5 MBq/kg), escalating in 0.5-mCi (18.5 MBq) increments to 3.0 mCi/kg (111 MBq/kg). Pain response after treatment was assessed as well as hematologic and serum chemistry parameters. Pain palliation with a mean duration of 2.6 mo was present in 74{\%} of the patients. Toxicity was exclusively hematologic at the highest dose levels. No infectious or bleeding complications occurred, with 45 of the 52 (86{\%}) patients demonstrating complete hematologic recovery. Patients receiving higher doses had significantly greater reductions in serum prostate specific antigen and serum prostatic acid phosphatase levels. The patients receiving greater doses also showed a trend toward improved survival.",
author = "C. Collins and Eary, {J. F.} and G. Donaldson and C. Vernon and Bush, {N. E.} and S. Petersdorf and Livingston, {Robert B} and Gordon, {E. E.} and Chapman, {C. R.} and Appelbaum, {F. R.}",
year = "1993",
language = "English (US)",
volume = "34",
pages = "1839--1844",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "11",

}

TY - JOUR

T1 - Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma

T2 - A phase I/II trial

AU - Collins, C.

AU - Eary, J. F.

AU - Donaldson, G.

AU - Vernon, C.

AU - Bush, N. E.

AU - Petersdorf, S.

AU - Livingston, Robert B

AU - Gordon, E. E.

AU - Chapman, C. R.

AU - Appelbaum, F. R.

PY - 1993

Y1 - 1993

N2 - Samarium-153-ethylenediaminetetramethylene phosphonic acid (EDTMP), a bone-seeking radiopharmaceutical, was given to prostate cancer patients in a dose escalation protocol for pain palliation to determine the maximally tolerated dose. Fifty-two patients with hormone refractory prostate cancer with bony metastases were treated with doses beginning at 0.5 mCi/kg (18.5 MBq/kg), escalating in 0.5-mCi (18.5 MBq) increments to 3.0 mCi/kg (111 MBq/kg). Pain response after treatment was assessed as well as hematologic and serum chemistry parameters. Pain palliation with a mean duration of 2.6 mo was present in 74% of the patients. Toxicity was exclusively hematologic at the highest dose levels. No infectious or bleeding complications occurred, with 45 of the 52 (86%) patients demonstrating complete hematologic recovery. Patients receiving higher doses had significantly greater reductions in serum prostate specific antigen and serum prostatic acid phosphatase levels. The patients receiving greater doses also showed a trend toward improved survival.

AB - Samarium-153-ethylenediaminetetramethylene phosphonic acid (EDTMP), a bone-seeking radiopharmaceutical, was given to prostate cancer patients in a dose escalation protocol for pain palliation to determine the maximally tolerated dose. Fifty-two patients with hormone refractory prostate cancer with bony metastases were treated with doses beginning at 0.5 mCi/kg (18.5 MBq/kg), escalating in 0.5-mCi (18.5 MBq) increments to 3.0 mCi/kg (111 MBq/kg). Pain response after treatment was assessed as well as hematologic and serum chemistry parameters. Pain palliation with a mean duration of 2.6 mo was present in 74% of the patients. Toxicity was exclusively hematologic at the highest dose levels. No infectious or bleeding complications occurred, with 45 of the 52 (86%) patients demonstrating complete hematologic recovery. Patients receiving higher doses had significantly greater reductions in serum prostate specific antigen and serum prostatic acid phosphatase levels. The patients receiving greater doses also showed a trend toward improved survival.

UR - http://www.scopus.com/inward/record.url?scp=0027521907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027521907&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 1839

EP - 1844

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 11

ER -